hydroxychloroquine has been researched along with Malaria in 41 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA)." | 7.75 | Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ( Bae, KS; Cho, JY; Choi, JS; Im, JS; Jang, IJ; Kim, TS; Klein, TA; Lim, HS; Park, JW; Yeom, JS, 2009) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 7.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| "Primaquine was shown to be a safe and effective prophylactic drug against both P." | 5.30 | Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. ( Regev-Yochay, G; Schwartz, E, 1999) |
| "Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria." | 5.05 | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. ( Cook, J; Joshi, A; Nicol, MR; Rizk, ML; Sabato, PE; Savic, RM; Wesche, D; Zheng, JH, 2020) |
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| "Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2." | 3.96 | Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. ( Al-Kofahi, M; Boulware, DR; Jaber, MM; Jacobson, P; Kandaswamy, R; Matas, A; Nicol, MR; Rajasingham, R; Young, JH, 2020) |
| "Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment." | 3.96 | Concentration-dependent mortality of chloroquine in overdose. ( Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020) |
| "To describe two patients that had induction and exacerbation of psoriasis due to the administration of hydroxychloroquine, to adapt pertinent literature on the pathophysiology of this side effect, to review psoriasis-triggered cases by newer, non-quinolinic antimalarials, and to propose malaria treatment and prophylaxis guidelines for psoriatic patients." | 3.80 | Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? ( Bassukas, ID; Gaitanis, G; Gravani, A; Zioga, A, 2014) |
| " Chloroquine or hydroxychloroquine are considered safe to use in all trimesters of pregnancy." | 3.77 | Prophylactic use of antimalarials during pregnancy. ( Bozzo, P; Einarson, A; Irvine, MH, 2011) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA)." | 3.75 | Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ( Bae, KS; Cho, JY; Choi, JS; Im, JS; Jang, IJ; Kim, TS; Klein, TA; Lim, HS; Park, JW; Yeom, JS, 2009) |
| "Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial." | 3.68 | Pregnancy outcome following first trimester exposure to chloroquine. ( Buskila, D; Gladman, DD; Koren, G; Levy, M; Urowitz, MB, 1991) |
| " Eleven volunteers received chloroquine in usually curative doses on a three-day schedule during acute clinical malaria attacks." | 3.64 | STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND. ( ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD, 1964) |
| "Plasmodium malariae is the only human malaria parasite species with a 72-hour intraerythrocytic cycle and the ability to persist in the host for life." | 1.46 | Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. ( Anstey, NM; Auburn, S; Berriman, M; Huang, GKL; Marfurt, J; Marr, I; Newbold, CI; Otto, TD; Price, RN; Rutledge, GG; Sanders, M; White, NJ, 2017) |
| "Primaquine was shown to be a safe and effective prophylactic drug against both P." | 1.30 | Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. ( Regev-Yochay, G; Schwartz, E, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (34.15) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 9 (21.95) | 24.3611 |
| 2020's | 12 (29.27) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, HS | 1 |
| Im, JS | 1 |
| Cho, JY | 1 |
| Bae, KS | 1 |
| Klein, TA | 1 |
| Yeom, JS | 1 |
| Kim, TS | 2 |
| Choi, JS | 1 |
| Jang, IJ | 1 |
| Park, JW | 1 |
| Tibon, NS | 1 |
| Ng, CH | 1 |
| Cheong, SL | 1 |
| Kucharski, DJ | 1 |
| Jaszczak, MK | 1 |
| Boratyński, PJ | 1 |
| Al-Kofahi, M | 1 |
| Jacobson, P | 1 |
| Boulware, DR | 1 |
| Matas, A | 1 |
| Kandaswamy, R | 1 |
| Jaber, MM | 1 |
| Rajasingham, R | 1 |
| Young, JH | 1 |
| Nicol, MR | 2 |
| Mvumbi, DM | 1 |
| Brest, P | 1 |
| Benzaquen, J | 1 |
| Klionsky, DJ | 1 |
| Hofman, P | 1 |
| Mograbi, B | 1 |
| Chen, X | 1 |
| Geiger, JD | 1 |
| Watson, JA | 1 |
| Tarning, J | 1 |
| Hoglund, RM | 1 |
| Baud, FJ | 1 |
| Megarbane, B | 1 |
| Clemessy, JL | 1 |
| White, NJ | 3 |
| Joshi, A | 1 |
| Rizk, ML | 1 |
| Sabato, PE | 1 |
| Savic, RM | 1 |
| Wesche, D | 1 |
| Zheng, JH | 1 |
| Cook, J | 1 |
| Coban, C | 1 |
| Schilling, WHK | 1 |
| Bancone, G | 1 |
| Matangila, JR | 1 |
| Nyembu, RK | 1 |
| Telo, GM | 1 |
| Ngoy, CD | 1 |
| Sakobo, TM | 1 |
| Massolo, JM | 1 |
| Muyembe, BM | 1 |
| Mvwala, RK | 1 |
| Ilunga, CK | 1 |
| Limbole, EB | 1 |
| Ntalaja, JM | 1 |
| Kongo, RM | 1 |
| Hussein, MIH | 1 |
| Albashir, AAD | 1 |
| Elawad, OAMA | 1 |
| Homeida, A | 1 |
| Rutledge, GG | 1 |
| Marr, I | 1 |
| Huang, GKL | 1 |
| Auburn, S | 1 |
| Marfurt, J | 1 |
| Sanders, M | 1 |
| Berriman, M | 1 |
| Newbold, CI | 1 |
| Anstey, NM | 1 |
| Otto, TD | 1 |
| Price, RN | 1 |
| Kim, HS | 1 |
| Kang, G | 1 |
| Lee, S | 1 |
| Yoon, CG | 1 |
| Kim, M | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Gravani, A | 1 |
| Gaitanis, G | 1 |
| Zioga, A | 1 |
| Bassukas, ID | 1 |
| LOUGHLIN, EH | 1 |
| RICE, JB | 1 |
| WELLS, HS | 1 |
| RAPPAPORT, I | 1 |
| JOSEPH, AA | 1 |
| Abdel-Hamid, H | 1 |
| Oddis, CV | 1 |
| Lacomis, D | 1 |
| ALVING, AS | 2 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Nebbioso, M | 1 |
| Grenga, R | 1 |
| Karavitis, P | 1 |
| TOLMAN, LL | 1 |
| Kobak, S | 1 |
| Deveci, H | 1 |
| Ben-Zvi, I | 1 |
| Kivity, S | 1 |
| Langevitz, P | 1 |
| Shoenfeld, Y | 1 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Koren, G | 2 |
| Irvine, MH | 1 |
| Einarson, A | 1 |
| Bozzo, P | 1 |
| Hong, YJ | 1 |
| Yang, SY | 1 |
| Lee, K | 1 |
| Kim, HB | 1 |
| Park, KU | 1 |
| Song, J | 1 |
| Kim, EC | 1 |
| HOEKENGA, MT | 3 |
| CLARK, HC | 1 |
| YOUNG, MD | 1 |
| POWELL, RD | 1 |
| BREWER, GJ | 1 |
| MILLAR, JW | 1 |
| RIZK, E | 1 |
| BERBERIAN, DA | 1 |
| DENNIS, EW | 1 |
| RUHE, DS | 1 |
| COOPER, WC | 1 |
| Schwartz, E | 1 |
| Regev-Yochay, G | 1 |
| Levy, M | 1 |
| Buskila, D | 1 |
| Gladman, DD | 1 |
| Urowitz, MB | 1 |
| Greenberg, AE | 1 |
| Kloser, P | 1 |
| Deloron, P | 1 |
| Williams, SB | 1 |
| Nesje, OA | 1 |
| Elslager, EF | 1 |
| Tendick, FH | 1 |
| Werbel, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441] | Phase 3 | 624 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.) | ||
| Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial[NCT04308668] | Phase 3 | 1,312 participants (Actual) | Interventional | 2020-03-17 | Completed | ||
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
| Non-Randomized Active Comparator | 0 |
Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Correlation coefficient (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks
| Intervention | Inflammatory markers (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Clinical factors (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 0 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Number of adverse events. (Number) | |
|---|---|---|
| Adverse events (only Level 1 and 2) observed in the study. | Serious adverse events (Level 3 or 4). | |
| Non-Randomized Active Comparator | 2 | 0 |
| Placebo | 188 | 0 |
| Study Drug - Daily Dose | 206 | 0 |
| Study Drug - Weekly Dose | 193 | 0 |
Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: baseline and 14 days
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment | -2.6 |
| Placebo | -2.33 |
Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 49 |
| Placebo | 58 |
Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 5 |
| Placebo | 8 |
Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 48 |
| Placebo | 55 |
Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 97 |
| Placebo | 63 |
Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 11 |
| Placebo | 9 |
Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial. (NCT04308668)
Timeframe: Approximately 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease. (NCT04308668)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 5 |
| Placebo | 9 |
Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: 5 and 14 days
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Day 5 | Day 14 | |
| Placebo | -2.05 | -3.08 |
| Treatment | -2.22 | -3.36 |
9 reviews available for hydroxychloroquine and Malaria
| Article | Year |
|---|---|
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular St | 2020 |
A Review of Modifications of Quinoline Antimalarials: Mefloquine and (hydroxy)Chloroquine.
Topics: Antimalarials; Chemistry Techniques, Synthetic; Humans; Hydroxychloroquine; Malaria; Mefloquine; Mod | 2022 |
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Topics: Age Factors; Aging; Antiviral Agents; Chloroquine; Clinical Trials, Phase II as Topic; Clinical Tria | 2020 |
The host targeting effect of chloroquine in malaria.
Topics: Animals; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Malaria; Pandemics; SARS- | 2020 |
Malaria and COVID-19: unmasking their ties.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy.
Topics: Antimalarials; Chloroquine; Early Diagnosis; Electroretinography; Humans; Hydroxychloroquine; Malari | 2009 |
Hydroxychloroquine: from malaria to autoimmunity.
Topics: Animals; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Autoimmune Diseases; Autoimm | 2012 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
32 other studies available for hydroxychloroquine and Malaria
| Article | Year |
|---|---|
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
Topics: Adult; Animals; Antimalarials; Area Under Curve; Female; Humans; Hydroxychloroquine; Malaria; Male; | 2009 |
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
Topics: Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Malari | 2020 |
Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Resist | 2020 |
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatmen | 2020 |
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cyt | 2020 |
Concentration-dependent mortality of chloroquine in overdose.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency.
Topics: Antimalarials; Chloroquine; COVID-19 Drug Treatment; Enzyme Inhibitors; Glucosephosphate Dehydrogena | 2020 |
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.
Topics: Adult; Aged; Blood Coagulation; Chloroquine; Coinfection; Comorbidity; Cough; COVID-19; COVID-19 Dru | 2020 |
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Dr | 2017 |
Cost-Benefit Analysis of Malaria Chemoprophylaxis and Early Diagnosis for Korean Soldiers in Malaria Risk Regions.
Topics: Chemoprevention; Cost-Benefit Analysis; Early Diagnosis; Humans; Hydroxychloroquine; Malaria; Milita | 2018 |
Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria?
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Infant, Newborn; Malaria; Practice Guideli | 2014 |
The treatment of Plasmodium falciparum malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-4(4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Malaria, Falciparum; Quinolines | 1952 |
Severe hydroxychloroquine myopathy.
Topics: Antimalarials; Female; Humans; Hydroxychloroquine; Malaria; Microscopy, Electron, Transmission; Midd | 2008 |
Study of pentaquine and isopentaquine, therapeutic agents effective in reducing relapse rate in vivax malaria.
Topics: Aminoquinolines; Hydroxychloroquine; Hydroxyquinolines; Malaria; Malaria, Vivax; Recurrence | 1948 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
Fluorine and sulfur quinoline derivatives as anti-malarial agents.
Topics: Antimalarials; Drug Therapy; Fluorides; Fluorine; Humans; Hydroxychloroquine; Malaria; Quinolines; S | 1946 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; | 2010 |
Prophylactic use of antimalarials during pregnancy.
Topics: Antimalarials; Atovaquone; Chemoprevention; Chloroquine; Doxycycline; Drug Combinations; Female; Hum | 2011 |
A case of imported Plasmodium malariae malaria.
Topics: Antimalarials; Drug Resistance; Female; Humans; Hydroxychloroquine; Malaria; Mefloquine; Plasmodium | 2012 |
Treatment of malaria with oral or intravenous plaquenil; a preliminary report.
Topics: Antimalarials; Hydroxychloroquine; Malaria | 1953 |
The suppressive treatment of malaria in a rural village with primaquine and plaquenil.
Topics: Antimalarials; Environment; Hydroxychloroquine; Malaria; Primaquine; Quinolines; Rural Population | 1954 |
The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Pyrimethamine | 1954 |
Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Plasmodium falciparum | 1961 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; D | 1964 |
The treatment of malaria with hydroxychloroquine.
Topics: Chloroquine; Hydroxychloroquine; Malaria | 1955 |
Mass suppression of hyperendemic vivax malaria with hydroxychloroquine.
Topics: Chloroquine; Humans; Hydroxychloroquine; Malaria; Malaria, Vivax | 1960 |
Studies in human malaria; the protective and therapeutic action of SN 6911 against St. Elizabeth strain vivax malaria.
Topics: Hydroxychloroquine; Malaria; Malaria, Vivax; Quinolines | 1949 |
Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antimalarials; Doxycycline; Female; Follow-Up Studies; | 1999 |
Pregnancy outcome following first trimester exposure to chloroquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Arthritis, Rheumatoid; Chloro | 1991 |
Assessment of possible drug-resistant Plasmodium falciparum in a pregnant traveller with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Drug Resistance, Microbial; Female; Humans; Hydroxychloroquine; Infant, | 1987 |
[Malignant malaria despite prevention with antimalarials].
Topics: Female; Humans; Hydroxychloroquine; Malaria; Middle Aged; Plasmodium falciparum; Travel | 1973 |
Repository drugs. 8. Ester and amide congeners of amodiaquine, hydroxychloroquine, oxychloroquine, primaquine, quinacrine, and related substances as potential long-acting antimalarial agents.
Topics: Amodiaquine; Animals; Antimalarials; Chemical Phenomena; Chemistry; Delayed-Action Preparations; Est | 1969 |